Why the study?
A novel cryoballoon device, POLARx, was recently introduced with unique features, but multicentre assessment of its periprocedural efficacy and safety was lacking.
Does POLARx cryoballoon-based PVI provide acute efficacy and safety in patients with paroxysmal or persistent AF?
Population
317 patients with paroxysmal or persistent AF in Germany and Italy
Comparison
POLARx cryoballoon-based pulmonary vein isolation
Design
Prospective multicenter observational study
Follow-up
Mean 226 ± 115 days
Authors
Loading...
High acute PVI success with post-learning-curve safety supports feasibility; leaves open randomized comparisons to established systems.
Does POLARx cryoballoon-based PVI provide acute efficacy and safety in patients with paroxysmal or persistent AF?
The novel POLARx cryoballoon system demonstrates high acute efficacy for pulmonary vein isolation and an acceptable safety profile that improves significantly after an initial learning curve.
Heeger et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: